Ethical dilemmas in the use of artificial intelligence in transfusion medicine

Comprehensive Summary

This study, presented by Seheult et. al, examines the growing integration of AI and machine learning workflows in blood banking and transfusion medicine. These tools can be used to extract signals from complex, large datasets to inform clinical decisionmaking and efficiency. The authors argue that while AI has potential to enhance donor recruitment, inventory forecasting, immunohematology interpretation, hemovigilance, and clinical decision support, these applications must be accompanied by rigorous ethical governance. The paper outlines how AI systems are already being developed to predict transfusion needs, optimize blood supply chains, interpret antibody screens, and monitor adverse transfusion reactions, helping improve clinical workflows. However, transfusion medicine is uniquely sensitive to public safety and trust issues due to its inherent reliance on volunteer donors and low tolerance for clinical error. High standards for validation, fairness testing, regulatory compliance, transparency, and human oversight are critical to address these concerns. Likewise, the authors propose an ethics framework tailored to transfusion medicine which includes five major domains: Safety and efficacy Fairness and equity Transparency and explainability Oversight and accountability Privacy and data rights Rather than outright rejecting AI, the authors advocate a process of "principled pragmatism", which balances innovation with disciplined validation and governance. The central focus is that AI should augment, not replace, clinical expertise, and must continue to operate within clearly defined human oversight systems.

Outcomes and Implications

This research addresses a central challenge for the future of artificial intelligence in clinical care. It reinforces that AI systems in healthcare cannot solely be evaluated on predictive accuracy. Algorithmic bias is seen as inevitable, which means that ethical deployment requires subgroup validation, especially in populations historically underrepresented in transfusion medicine. Additionally, the article emphasizes continuous post deployment monitoring, as AI models can degrade over time due to data drift. This means that implementation should be framed as an ongoing responsibility requiring surveillance and recalibration rather than a single event. Furthermore, the authors highlight that transparency and accountability are fundamental in maintaining donor and patient trust, but privacy protections must evolve alongside AI expansion. AI should enhance human judgement rather than automate it away. Overreliance on AI may lead to deskilling among clinicians, reducing their ability to detect anomalies or model errors. Thus, as the role of AI continues to grow in medicine, human expertise through structured oversight is critical.